Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc has exhibited consistent growth in its EsoGuard testing volume, processing 2,841 tests in Q3, marking an increase from previous quarters, which indicates a positive trajectory in product adoption. This growth, alongside its diverse pipeline of medical technologies, positions the company favorably within the medical technology sector, highlighting substantial upside potential relative to its current share price. Furthermore, the opportunity for significant expansion in 2025 and 2026 for its products underscores the attractive valuation of PAVmed, balancing its inherent risks with the promise of future revenue growth.

Bears say

PAVmed Inc has reported a pro forma net loss of $0.8 million, which is inconsistent with previous estimates and highlights ongoing financial challenges, including a negative earnings per share (EPS) of $(0.05). The company has also experienced a decline in the number of EsoGuard tests processed, dropping from 3,034 in Q1 to 2,756 in Q2, indicating potential issues with demand or market penetration for its diagnostic products. Furthermore, with early-stage commercialization efforts and significant risks regarding regulatory approvals, reimbursement, and competition, PAVmed's ability to generate substantial revenue and sustain growth in its product pipeline remains uncertain, ultimately contributing to a negative outlook for its stock.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.